利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.063 秒)

    Diagnosis of sepsis or SIRS using biomarker profiles
    4.
    发明申请
    Diagnosis of sepsis or SIRS using biomarker profiles 审中-公开
    使用生物标志物图谱诊断败血症或SIRS

    公开(公告)号：US20080138832A1

    公开(公告)日：2008-06-12

    申请号：US11904282

    申请日：2007-09-25

    申请人： Richard M. Ivey ,  Thomas M. Gentle ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur ,  Robert W. Rosenstein ,  James G. Nadeau ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    发明人： Richard M. Ivey ,  Thomas M. Gentle ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur ,  Robert W. Rosenstein ,  James G. Nadeau ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    IPC分类号： G01N33/53 ,  C12Q1/02 ,  G01N33/00

    CPC分类号： G01N33/6803 ,  C12Q1/6837 ,  C12Q1/686 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2800/26

    摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

    摘要翻译： 败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。 通过将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较来实现早期预测或诊断，其可包括发生败血症的群体。 识别个体生物标志物特征的特征是脓毒症发作的特征允许临床医生在单个时间点诊断从个体分离的体液的败血症发作。 因此，避免在一段时间内监测患者的必要性，有利地允许在脓毒症严重症状发作之前进行临床干预。 此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。 个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

    Diagnosis of sepsis or SIRS using biomarker profiles
    5.
    发明授权
    Diagnosis of sepsis or SIRS using biomarker profiles 有权
    使用生物标志物图谱诊断败血症或SIRS

    公开(公告)号：US07645573B2

    公开(公告)日：2010-01-12

    申请号：US10704666

    申请日：2003-11-12

    申请人： Richard M. Ivey ,  Thomas M. Gentle, Jr. ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur, Jr. ,  Robert W. Rosenstein ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    发明人： Richard M. Ivey ,  Thomas M. Gentle, Jr. ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur, Jr. ,  Robert W. Rosenstein ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q1/6837 ,  C12Q1/686 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/26

    摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

    摘要翻译： 败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。 使用分子诊断方法实现早期预测或诊断，包括将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较，其可包括发生败血症的群体。 识别个体生物标志物特征的特征是脓毒症发作的特征，允许临床医生在单个时间点从个体分离的体液诊断败血症的发作。 因此，避免在一段时间内监测患者的必要性，有利地允许在严重症状发作之前进行临床干预。 此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。 个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

    Solid phase chromatographic immunoassay
    6.
    再颁专利
    Solid phase chromatographic immunoassay 有权
    固相色谱免疫测定

    公开(公告)号：USRE38430E1

    公开(公告)日：2004-02-17

    申请号：US09167028

    申请日：1998-10-06

    申请人： Robert W. Rosenstein

    发明人： Robert W. Rosenstein

    IPC分类号： G01N33558

    CPC分类号： G01N33/558 ,  G01N30/90

    摘要： A chromatographic test strip comprising a solid support having at least a first portion and a second portion with said portions being in the same plane so as to permit capillary flow communication with each other. The sample is added to the first portion. The first portion also may comprise a tracer portion having a tracer movably supported therein. The tracer consists of a visible particulate marker. In the second portion, a binder is immobilized. The test strip is useful in a variety of immunoassays.

    Purification of antibodies
    8.
    发明授权
    Purification of antibodies 失效
    抗体的纯化

    公开(公告)号：US4841024A

    公开(公告)日：1989-06-20

    申请号：US907404

    申请日：1986-09-15

    申请人： Gene R. Nathans ,  Robert W. Rosenstein

    发明人： Gene R. Nathans ,  Robert W. Rosenstein

    IPC分类号： C07K16/06

    CPC分类号： C07K16/065 ,  Y10S424/804 ,  Y10S435/803 ,  Y10S530/861

    摘要： I(g)G3 antibody is purified by affinity chromatography and collection of released antibody at a pH of 9.0 to 9.6. The purification is effected in a column containing both an affinity matrix and a desalting matrix, with the column being equilibrated to a pH of from 9.0 to 9.6. I(g)G3 antibody may be stored at pH 9.0 to 9.6.

    摘要翻译： I（g）G3抗体通过亲和层析纯化，并在9.0至9.6的pH下收集释放的抗体。 纯化在含有亲和基质和脱盐基质的柱中进行，柱平衡至9.0-9.6的pH。 I（g）G3抗体可以在pH 9.0〜9.6保存。